{"id":62090,"date":"2025-10-25T19:03:27","date_gmt":"2025-10-25T17:03:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/setpoint-medical-to-present-data-at-acr-convergence-2025-demonstrating-sustained-efficacy-and-safety-for-the-setpoint-system-to-treat-rheumatoid-arthritis\/"},"modified":"2025-10-25T19:03:27","modified_gmt":"2025-10-25T17:03:27","slug":"setpoint-medical-to-present-data-at-acr-convergence-2025-demonstrating-sustained-efficacy-and-safety-for-the-setpoint-system-to-treat-rheumatoid-arthritis","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/setpoint-medical-to-present-data-at-acr-convergence-2025-demonstrating-sustained-efficacy-and-safety-for-the-setpoint-system-to-treat-rheumatoid-arthritis\/","title":{"rendered":"SetPoint Medical to Present Data at ACR Convergence 2025 Demonstrating Sustained Efficacy and Safety for the SetPoint System to Treat Rheumatoid Arthritis"},"content":{"rendered":"
\n

\nFour presentations highlight 12-month clinical outcomes, as well as MRI-assessed joint protection and patient perspectives supporting the SetPoint System as first-of-its-kind treatment for rheumatoid arthritis (RA)<\/i><\/p>\n

VALENCIA, Calif.–(BUSINESS WIRE)–SetPoint Medical<\/a>, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today announced it will share four presentations highlighting new data about the SetPoint System at the upcoming American College of Rheumatology (ACR) Convergence 2025, the largest global gathering of rheumatologists. Presentations will include clinical data demonstrating that the first-of-its-kind SetPoint System\u2019s neuroimmune modulation therapy provides sustained clinical efficacy over 12 months, inhibits joint erosion progression, and is of strong interest to adults living with moderate-to-severe rheumatoid arthritis (RA), particularly among those not satisfied with current biologic or Janus kinase (JAK) inhibitor treatments.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cThe RESET-RA data document sustained clinical efficacy through one year of therapy indicating that neuroimmune modulation is effective for RA, including for those who have inadequate response to one or more biologic or JAK inhibitors,\u201d said David Chernoff, M.D., Chief Medical Officer of SetPoint Medical. \u201cImportantly, magnetic resonance imaging (MRI) data provides objective evidence that the SetPoint System inhibits progression of joint erosions as early as three months.\u201d<\/p>\n

\nThe data are based on outcomes from the RESET-RA study, a pivotal, randomized, sham-controlled, double-blind trial of 242 patients with moderately to severely active RA who were incomplete responders or intolerant to at least one biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b\/tsDMARDs). The study met its primary efficacy endpoint and demonstrated a favorable safety profile leading to FDA approval<\/a> for the SetPoint System in July 2025.<\/p>\n

\n\u201cWe\u2019re thrilled with the breadth of data being presented at ACR, further demonstrating the potential of the SetPoint System in treating people living with RA,\u201d said Murthy V. Simhambhatla, Ph.D., CEO of SetPoint Medical. \u201cThe patient preference findings reveal that individuals with RA\u2014particularly those with prior biologic exposure\u2014view this treatment approach positively, underscoring the need for more therapeutic options that are safe and effective.\u201d<\/p>\n

\nACR 2025 Abstract Details<\/span><\/b><\/p>\n

\nAbstract 2278: Neuroimmune Modulation for the Treatment of Rheumatoid Arthritis: Results at 12 Months from a Randomized, Sham-Controlled, Double-Blind Study<\/b><\/p>\n

\nTwelve-month data from the RESET-RA study showed that SetPoint System achieved durable efficacy, sustained disease improvement, and a favorable safety profile in adults with rheumatoid arthritis who had an inadequate response or intolerance to biologic or targeted synthetic DMARDs, such as JAK inhibitors.<\/p>\n

\nKey Findings:<\/p>\n